Frequency of ctDNA Testing and Future Directions in Detecting MRD

Opinion
Video

Experts on colorectal cancer share insights on optimizing the frequency of ctDNA detection and discuss potential ways to overcome challenges associated with MRD detection.

Recent Videos
2 experts in this video
Related Content
Efficacy data from the phase 1/2a STELLA trial evaluating alnodesertib plus irinotecan in those with ATM-negative disease support the regulatory decision.

Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC

Roman Fabbricatore
September 24th 2025
Article

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening

Russ Conroy
September 6th 2025
Article

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 27th 2025
Article

TAS-102 had a significant impact, achieving ctDNA clearance, in patients with colorectal cancer with ctDNA-defined MRD.

Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.

Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC

Roman Fabbricatore
August 26th 2025
Article

Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.